Pirfenidone inhibits proliferation, arrests the cell cycle, and downregulates heat shock protein-47 and collagen type I in rat hepatic stellate cells in vitro.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Molecular Medicine Reports

• Publication date

  2015-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/mmr.2015.3403PMID 25738437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amendment history : Corrigendum ( April 2005 ) Liver fibrosis Ramón Bataller

  2018cited by this paper
• Pirfenidone restricts Th2 differentiation in vitro and limits Th2 response in experimental liver fibrosis.

  2012cited by this paper
• [Idiopathic pulmonary fibrosis: modern guideline-concordant diagnostics and innovative treatment].

  2012cited by this paper
• Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis.

  2012cited by this paper
• Heat Shock Protein 47 (HSP47) Antisense Oligonucleotides Reduce Cardiac Remodeling and Improve Cardiac Function in a Rat Model of Myocardial Infarction

  2011cited by this paper
• Pharmacokinetics of pirfenidone after topical administration in rabbit eye

  2011cited by this paper
• Effect of heat shock protein 47 on collagen synthesis of keloid in vivo

  2011cited by this paper
• Heat shocks enhance procollagen type I and III expression in fibroblasts in ex vivo human skin

  2011cited by this paper
• Heat Shock Protein 47: A Novel Biomarker of Phenotypically Altered Collagen-Producing Cells

  2011cited by this paper
• Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro.

  2009cited by this paper
• Pirfenidone inhibits carbon tetrachloride‐ and albumin complex‐induced liver fibrosis in rodents by preventing activation of hepatic stellate cells

  2009cited by this paper
• Resolution of liver cirrhosis using vitamin A–coupled liposomes to deliver siRNA against a collagen-specific chaperone

  2008cited by this paper
• Effects of three anti-TNF-α drugs : Etanercept , infliximab and pirfenidone on release of TNF-α in medium and TNF-α associated with the cell in vitro

  2008cited by this paper
• Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro.

  2008cited by this paper
• Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts.

  2008influential reference
• Potent antioxidant role of pirfenidone in experimental cirrhosis.

  2008cited by this paper
• Current and future anti-fibrotic therapies for chronic liver disease.

  2008cited by this paper
• Fibrogenic Polymorphisms (TGF-β, PAI-1, AT) in Mexican Patients With Established Liver Fibrosis. Potential Correlation With Pirfenidone Treatment

  2008cited by this paper
• Suppression of Renal Tubulointerstitial Fibrosis by Small Interfering RNA Targeting Heat Shock Protein 47

  2007cited by this paper
• The collagen-specific molecular chaperone HSP47: is there a role in fibrosis?

  2007cited by this paper
• Hsp47 a novel collagen binding serpin chaperone, autoantigen and therapeutic target.

  2005cited by this paper
• Expression of HSP47, a collagen-specific chaperone, in normal and diseased human liver

  2005cited by this paper
• Heat shock protein 47 and renal fibrogenesis.

  2005cited by this paper
• Liver fibrosis.

  2005cited by this paper
• Management of cirrhosis and ascites.

  2004cited by this paper
• Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis

  2004cited by this paper
• [Therapeutic strategy for fibrotic diseases by regulating the expression of collagen-specific molecular chaperone HSP47].

  2003cited by this paper
• Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats

  2003cited by this paper
• The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2.

  2003cited by this paper
• Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats.

  2003cited by this paper
• Inhibition of type I procollagen production by tRNAVal CTE‐HSP47 ribozyme

  2003cited by this paper
• Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock.

  2002cited by this paper
• Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production.

  2002influential reference
• Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis.

  2001cited by this paper
• Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin‐diabetic rats

  2001cited by this paper
• Pirfenidone Inhibits Dimethylnitrosamine‐Induced Hepatic Fibrosis In Rats

  2001cited by this paper
• Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury*

  2000influential reference
• Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level.

  1999cited by this paper
• Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level.

  1999cited by this paper
• Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress collagen accumulation in experimental glomerulonephritis.

  1998cited by this paper
• Hsp47 and the translation-translocation machinery cooperate in the production of alpha 1(I) chains of type I procollagen.

  1994cited by this paper
• Cellular localization of type I III and IV procollagen gene transcripts in normal and fibrotic human liver.

  1990influential reference

• Pirfenidone Alleviates Intrauterine Infection‐Induced Lung Injuries in Neonates by Targeting Transforming Growth Factor Beta 1/Sma‐ and Mad‐Related Protein Signaling Pathway

  2025cites this paper
• A Novel Protein‐Polysaccharide Oral Nanoemulsion Targeting Activated Hepatic Stellate Cells to Enhance the Therapeutic Effect of Pirfenidone on Fibrosis After Transarterial Chemoembolization for Liver Cancer

  2025cites this paper
• An in vitro 3D spheroid model with liver steatosis and fibrosis on microwell arrays for drug efficacy evaluation.

  2025cites this paper
• Pirfenidone promotes cell cycle arrest and apoptosis of triple‑negative breast cancer cells by suppressing Hedgehog/GLI1 signaling

  2024cites this paper
• Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond

  2022cites this paper
• Wound healing activity of the hydroalcoholic extract and the main metabolites of Amphipterygium adstringens (cuachalalate) in a rat excision model.

  2022cites this paper
• HSP47: a potential target for fibrotic diseases and implications for therapy.

  2020cites this paper
• Hepatic Antifibrotic Pharmacotherapy: Are We Approaching Success?

  2020cites this paper
• Pirfenidone, an Anti-Fibrotic Drug, Suppresses the Growth of Human Prostate Cancer Cells by Inducing G1 Cell Cycle Arrest

  2019cites this paper
• Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities

  2019cites this paper
• Pathologic features and expression of heat shock protein 47 in the nasal mucosa and lacrimal sac: does it influence the surgical outcome of endoscopic endonasal dacryocystorhinostomy?

  2018cites this paper
• A fully automated image analysis method to quantify lung fibrosis in the bleomycin-induced rat model

  2018cites this paper
• Effects of pirfenidone in acute and sub‐chronic liver fibrosis, and an initiation‐promotion cancer model in the mouse

  2018cites this paper
• Heat shock protein 47 effects on hepatic stellate cell-associated receptors in hepatic fibrosis of Schistosoma japonicum-infected mice

  2017cites this paper
• Anti-fibrotic effect of pirfenidone in muscle derived-fibroblasts from Duchenne muscular dystrophy patients.

  2016cites this paper
• Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis.

  2016cites this paper
• The next generation of therapeutics for chronic kidney disease

  2016cites this paper
• Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts

  2016cites this paper
• Emodin alleviates bleomycin-induced pulmonary fibrosis in rats.

  2016cites this paper
• Non-coding RNA-mediated epigenetic regulation of liver fibrosis.

  2015cites this paper